Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
IDWeek
IDWeek
IDWeek
is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP).
Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
IDWeek 2018
Omadacycline is a new intravenous/oral antibiotic for patients presenting in the emergency department with acute bacterial skin and soft tissue infections.
Read More ›
Pooled Analysis of Patients with Wound Infections in the Phase 3 REVIVE Trials Comparing Iclaprim with Vancomycin
IDWeek 2018
In 2 parallel phase 3 trials, the diaminopyrimidine reductase inhibitor iclaprim showed noninferiority compared with vancomycin for the treatment of wound infections.
Read More ›
Health-Related Social Vulnerabilities in a Pediatric Outpatient Antimicrobial Therapy Program
IDWeek 2018
Identifying social vulnerabilities that likely impact pediatric outpatient antimicrobial treatment after discharge could better enable treatment customization or prompt care coordination.
Read More ›
Oral Step-Down Therapy with Fluoroquinolones versus Beta-Lactams for Hospitalized Patients with Community-Acquired Pneumonia
IDWeek 2018
Although community-acquired pneumonia (CAP) guidelines recommend transition to an oral beta-lactam regimen or fluoroquinolone (FQ) when patients are clinically stable, the collateral damage associated with FQ usage has led stewardship efforts to reduce initial FQ usage in CAP therapy.
Read More ›
FDA Approves NUZYRA™ (Omadacycline) for Community-Acquired Bacterial Pneumonia and Acute Skin and Skin Structure Infections
IDWeek 2018
The US Food and Drug Administration has approved omadacycline for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Read More ›
New Robust Antimicrobial Stewardship Program Results in Reduction of Clostridium Difficile 30-Day Readmission
IDWeek 2018
A dedicated infectious disease stewardship program can have immediate impact on patient safety, treatment of appropriate disease states, and the reduction of unnecessary readmission to the acute care hospital.
Read More ›
Longer Duration of Antibiotic Therapy for Community-Acquired Pneumonia and Risk for Clostridium Difficile Infection
IDWeek 2018
Shortening the duration of antimicrobial therapy to that recommended in guidelines may reduce the risk for collateral damage due to
Clostridium difficile
infection.
Read More ›
Antimicrobial Stewardship Program Aims to Reduce Antimicrobial Usage in Geriatric Patients without Affecting Outcomes
IDWeek 2018
The researchers assessed the impact of antimicrobial stewardship program interventions in elderly patients on 30-day readmissions due to treatment failure and decreased antibiotic expenditures per adjusted patient-day.
Read More ›
Integrated Safety Summary of Omadacycline, A Novel Aminomethylcycline Antibiotic
IDWeek 2018
A pooled analysis showed favorable safety results from phase 3 studies of omadacycline, a new once-daily intravenous/oral therapy for the monotherapy of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Read More ›
Pooled Analysis of Safety Data from Phase 2 and 3 Clinical Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections
IDWeek 2018
Pooled safety data of eravacycline in 3 comparator-controlled studies for the treatment of complicated intra-abdominal infections showed that it was generally well-tolerated compared with ertapenem and meropenem.
Read More ›
Page 2 of 3
1
2
3
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us